Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
S H Kelkar and Company announces Q2 & H1 FY17 results - The Pharma Times | Pharma & Health Care News Portal
Categories: Financial Results

S H Kelkar and Company announces Q2 & H1 FY17 results

H1 FY17

Total Income up 17% to Rs. 501 crore

EBITDA improves 36% to Rs. 95 crore

PAT grew by 96% to Rs 52 crore

Mumbai, November 15, 2016: S H Kelkar and Company, the largest Indian-origin Fragrance and Flavours Company in India,has announced its financial results for the quarter ended September 30, 2016.

H1 FY17 performance overview compared with H1 FY16___________________________________________________

  • Total Income grew by 17% to Rs. 501 crore from Rs. 429 crore
  • EBITDA increases by 36% to Rs. 95 crore from Rs. 70 crore
    • EBITDA margin improvesby 265 bps to 19%
  • Profit Before Tax higher by 100% to Rs. 82 crore from Rs. 41 crore
  • Profit After Tax increases by 96% at Rs. 52 crore compared to Rs. 27 crore

Q2 FY17 performance overview compared with Q2FY16___________________________________________________

  • Total Income grew by 18% to Rs. 245 crore from Rs. 208crore
  • EBITDA increases by 60% to Rs. 45crore from Rs. 28crore
    • EBITDA margin improves by 481bps to 18.1%
  • Profit Before Tax higher by 186% to Rs.37 crore from Rs.13crore
  • Profit After Tax increases by 247% at Rs. 24crore compared to Rs. 7crore

Key Developments_________________________________________________________________________________

  • Executed Business Transfer Agreement (BTA) with Gujarat Flavours Private Limited (GFPL) for acquisition of the Company’s flavours division
    • The Company expects to complete the acquisition process in Q3 FY2017
    • GFPL is a Vadodara-based 34-year old entity; the Company’s flavour division reported a topline of Rs. 10.5 crore in FY16
    • Acquisition is in-line with the Company’s plan to pursue strategic tuck-in acquisitions to increase its market share in the Flavours business

Commenting on the results, Mr. Kedar Vaze, Chief Executive Officer and Director at SH Kelkar and Company said,

“I am pleased to report yet another strong quarter on the back of healthy volumes and improved realizations.The domestic division continued to deliver robust topline growth of 26%, while the performance in the international segment was muted.

Going forward, we expect the global macro-economic environment to remain subdued in the near-term; however we believe the Indian consumption story should enable us to report results in-line with our business plan. We remain at the forefront of the ever evolving consumer landscape. Our investments in R&D will continue to drive innovation and growth in this niche industry.”

Corporate Comm India(CCI Newswire)

 

The Pharma Times News Bureau

Recent Posts

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

3 days ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

5 days ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

2 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago

Ankura Hospital Doctors perform a successful Complex Lung Surgery on a 4-month-old Infant

 Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…

3 weeks ago